Latest / Pricing Power Podcast with Fexingo: How Businesses Set Prices, Raise Margins, and Win Customers / How the Makers of Ozempic and Wegovy Price Their Miracle Drugs
Transcript
- Lucas: Luna, I want to talk about a pricing story that's unfolding in real time, and it involves a drug you've probably heard of if you follow business news at all: Ozempic. Or Wegovy. Or, for that matter, Mounjaro. But we're going to focus on the company that makes the first two: Novo Nordisk. Luna: You're talking about the GLP-1 class of drugs, right? The ones that have basically taken over the conversation around weight loss and diabetes? Lucas: Exactly. And here's the starting point that I think is really interesting: the list price for a month's supply of Wegovy in the United States is about $1,350. That's roughly $16,000 a year for a drug that patients often take indefinitely. Meanwhile, in the United Kingdom, the National Health Service pays something like a quarter of that. Luna: Sixteen thousand dollars a year. That's a lot of money. But I've also read that Novo Nordisk doesn't actually get that full amount, right? Because of rebates and discounts. Lucas: Right. There's a big gap between list price and net price. And that gap is partly driven by pharmacy benefit managers, or PBMs. PBMs negotiate rebates from drug manufacturers in exchange for favorable placement on insurance formularies. So Novo Nordisk might set a high list price, but then they pay rebates to PBMs that bring the net price down. Some analysts estimate the net price for Wegovy after rebates is around $800 to $900 a month. Still very high, but not $1,350. Luna: So why not just set the list price lower in the first place? Why go through this complicated rebate system? Lucas: Great question. The reason is that PBMs and insurers want high list prices too, in a weird way. Because the rebate is a percentage of the list price, a higher list price means a bigger rebate. And PBMs can then use those rebates to lower premiums for their entire member base. So there's a perverse incentive for everyone except the patient, especially if the patient's insurance requires a co-pay tied to the list price. Luna: That's a good example of how opaque pharmaceutical pricing really is. The patient at the pharmacy counter might be charged a co-pay based on that $1,350 list price, even if the insurer paid much less after rebates. Lucas: Exactly. And that's one of the reasons there's been so much political pressure on drug pricing. But Novo Nordisk has some unique advantages that give it pricing power. First, the patent protection on semaglutide — that's the active ingredient in Ozempic and Wegovy — is quite strong, and it doesn't expire until at least 2032 in the US, with some extensions possible. Luna: So they have a monopoly on the molecule. But there are competitors, right? Eli Lilly's Mounjaro, for instance, which is tirzepatide. And there are other drugs in the pipeline. Lucas: That's true. But the market is growing so fast that even with competition, demand is outstripping supply. Novo Nordisk has been capacity-constrained for years. They're spending billions to build new manufacturing plants. In the meantime, they can't make enough Wegovy to meet global demand. And when supply is tight, you don't have to cut prices. Luna: So the pricing power comes from a combination of patent protection, surging demand, and limited supply. It's a perfect storm for the company's margins. Lucas: It is. And Novo Nordisk has become the most valuable company in Europe by market capitalization — it recently passed LVMH. That's partly driven by the GLP-1 franchise. In 2023, Ozempic alone brought in about $14 billion in revenue. Wegovy added another $4.5 billion. And those numbers are growing fast. Luna: But there's another angle here: the Inflation Reduction Act. Starting in 2026, Medicare will be able to negotiate prices for certain high-spend drugs. And Ozempic is expected to be one of the first drugs selected for negotiation. Lucas: That's a big looming risk. If Medicare negotiates a lower price for Ozempic, that could set a precedent for Wegovy and other GLP-1s. Novo Nordisk is fighting this in court, but it's a real threat to their pricing model. However, the negotiation only applies to drugs that have been on the market for at least nine years for small molecules, and thirteen years for biologics. Semaglutide is a biologic, so the earliest Medicare could negotiate would be 2031 or so, depending on the specific approval dates. Luna: That gives them a few more years of full pricing power. But in the meantime, there's another threat: compounding pharmacies. These are pharmacies that make custom versions of drugs, and they've been producing semaglutide during the shortage. The FDA allows compounding when a drug is in shortage, and Wegovy has been on the shortage list for a while now. Lucas: Right. Compounded semaglutide can cost a fraction of the brand-name drug — sometimes $200 to $400 a month. And patients can get it without insurance. That's a real competitive pressure, even if the compounded versions aren't fda approved and come with some risks. Novo Nordisk has been trying to get the FDA to declare the shortage over, which would halt compounding. But the FDA hasn't done that yet. Luna: So it's a bit of a game of whack a mole. They have pricing power from patents and demand, but they face pressure from compounding, potential Medicare negotiation, and eventual generic competition. Lucas: Exactly. And that's why you see Novo Nordisk investing heavily in next-generation drugs. They have a pill formulation of semaglutide in late-stage trials, which could be even more convenient and extend their patent coverage. They're also working on combination drugs that could treat obesity and other conditions like NASH or cardiovascular disease. The idea is to always have a new product ready before the old one loses exclusivity. Luna: That's a classic pharmaceutical strategy. But there's something unique about GLP-1s: they're not just for diabetes or obesity anymore. There are trials showing benefits for heart failure, kidney disease, even Alzheimer's and addiction. If those indications pan out, the addressable market becomes enormous — potentially hundreds of millions of patients. Lucas: And that would justify even higher pricing, at least from a value perspective. But it also raises the stakes for public scrutiny. If a drug that could help millions of people is priced at $1,350 a month, that creates a lot of tension between the company's profit motive and public health. Luna: So how do you see this playing out over the next few years? Do they keep the price high, or eventually bring it down? Lucas: I think in the short term, they keep it high. Demand is still growing faster than supply. But as more competitors enter — and there are dozens of GLP-1s in development — the pricing pressure will increase. By the time the patent expires, the net price will likely be much lower. But that's a decade away. In the meantime, Novo Nordisk is going to extract as much value as it can. It's rational, but it's also controversial. Luna: You know, speaking of value, this is the kind of conversation that I think is genuinely useful for business listeners. It's not just about the drugs — it's about understanding how a company can maintain pricing power even in a highly regulated industry. Lucas: Absolutely. And it's exactly why we do this show ad-free. We want these insights to be accessible without a commercial break in the middle. If you find value in these episodes, you can support the show at buy me a coffee dot com slash fexingo. That link helps us keep the podcast independent and focused on the substance, not the ads. Luna: Yeah, it's a small way to make sure we can keep digging into topics like this. And we appreciate everyone who has chipped in so far. Lucas: So back to Novo Nordisk. The key takeaway for me is that pricing power in pharma is about more than just patents. It's about managing the entire ecosystem: supply chains, regulatory timelines, public perception, and the competitive landscape. Novo Nordisk has done that exceptionally well, but the next decade will test whether they can adapt. Luna: And for the listener — if you're in any business where you have a product with strong demand, you can learn from their playbook. Control the supply, protect your intellectual property, and think about the next generation before the current one matures. Lucas: That's the lesson. Thanks for listening, everyone. We'll be back next time with another deep dive into the economics of pricing.